Skip to content

The Study of EIT-guided Ventilation Strategy on ARDS Patients

The Study of EIT-guided Ventilation Strategy on ARDS Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04734340
Enrollment
100
Registered
2021-02-02
Start date
2021-01-01
Completion date
2023-06-01
Last updated
2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Pulmonary Perfusion

Keywords

EIT, ARDS, pulmonary perfusion

Brief summary

This study is a clinical randomized controlled study.The objective of this study is to compare the prognosis of patients with ARDS between eit-v / q-oriented individualized ventilation strategy and traditional lung protection ventilation strategy, and to establish the demonstration application of eit-v / q-oriented ventilation strategy in ARDS

Interventions

PROCEDUREEIT-guided PEEP setting

Ventilator parameter setting by EIT

PROCEDUREARDS-net PEEP setting

Ventilator parameter setting according to ARDS-net table

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. According to ARDS Berlin standard, ARDS, PaO2 / FiO2 \< 200mmhg, peep \> 5cmh2o; 2. According to clinical judgment, lung recruitment therapy is needed due to hypoxemia; 3. The subjects or their families signed informed consent. 4. Admission to ICU was less than 72 hours; 5. The estimated duration of mechanical ventilation was more than or equal to 48 hours; 6. Age ≥ 18 years old and ≤ 80 years old;

Exclusion criteria

1. The patients with heart implants could not be monitored by EIT; 2. Patients or their families refused to participate in the study; 3. Hypernatremia

Design outcomes

Primary

MeasureTime frame
ventilation free days1 Day

Secondary

MeasureTime frame
28-day mortality28 days

Countries

China

Contacts

Primary ContactYun Long
ly_icu@aliyun.com13911608699
Backup ContactSiyi Yuan
yuansiyizqh@163.com15201518815

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026